
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
In a continuing series from Dermatology Times , a panel of pediatric masters discusses treatment options for specific and unusual cases. This second case is that of a 13-year-old girl who presents a progressive area of alopecia over the frontal parietal scalp. There is an ivory scleratic plaque with an extension to the forehead. What do you do?






